Rewind Therapeutics

Rewind Therapeutics is developing novel re-myelinating therapies for patients suffering from Multiple Sclerosis and other myelin-related diseases. In close collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3), Axxam S.p.A. and a world-class academic network, Rewind Therapeutics aspires to advance innovative first-in-class therapies to the clinic. Rewind Therapeutics is based in Leuven, Belgium.